Garden Grove, CALIFORNIA3 Active Studies

Pulmonary Embolism Clinical Trials in Garden Grove, CALIFORNIA

Find 3 actively recruiting pulmonary embolism clinical trials in Garden Grove, CALIFORNIA. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
840
Enrolling

Recruiting Pulmonary Embolism Studies in Garden Grove

About Pulmonary Embolism Clinical Trials in Garden Grove

Pulmonary embolism (PE) is a blockage of an artery in the lungs, usually caused by blood clots that travel from the deep veins of the legs. It can be life-threatening and requires immediate medical attention. Treatment includes anticoagulants and in severe cases, thrombolytic therapy.

There are currently 3 pulmonary embolism clinical trials recruiting participants in Garden Grove, CALIFORNIA. These studies are seeking a combined 840 participants. Research is being sponsored by AstraZeneca, Novartis Pharmaceuticals, Immunis, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Embolism Clinical Trials in Garden Grove — FAQ

Are there pulmonary embolism clinical trials in Garden Grove?

Yes, there are 3 pulmonary embolism clinical trials currently recruiting in Garden Grove, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Garden Grove?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Garden Grove research site will contact you about next steps.

Are clinical trials in Garden Grove free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Garden Grove studies also compensate for your time and travel.

What pulmonary embolism treatments are being tested?

The 3 active trials in Garden Grove are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary embolism.

Data updated March 2, 2026 from ClinicalTrials.gov